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A B S T R A C T
Signal Inhibitory Receptor on Leukocytes-1 (SIRL-1) is expressed on human blood monocytes and granulocytes
and inhibits myeloid effector functions. On monocytes, but not granulocytes, SIRL-1 expression is low or absent
in individuals with the single nucleotide polymorphism (SNP) rs612529C. The expression of SIRL-1 in tissue and
the influence of rs612529 hereon is currently unknown. Here, we used flow cytometry to determine SIRL-1
expression on immune cells in human blood and three barrier tissues; skin, colon and lung. SIRL-1 was expressed
by virtually all neutrophils and eosinophils in these tissues. In contrast, SIRL-1 was not expressed by monocyte-
derived cells in skin and colon, whereas it was highly expressed by lung classical monocytes. Lung monocytes
from individuals with a rs612529C allele had decreased SIRL-1 expression, consistent with the genotype asso-
ciation in blood. Within the different monocyte subsets in blood and lung, SIRL-1 expression was highest in
classical monocytes and lowest in nonclassical monocytes. SIRL-1 was not expressed by dendritic cells in blood
and barrier tissues. Together, these results indicate that SIRL-1 is differentially expressed on phagocyte subsets in
blood and barrier tissues, and that its expression on monocytes is genotype- and tissue-specific. Immune reg-
ulation of monocytes by SIRL-1 may be of particular importance in the lung.
1. Introduction
Phagocytes, a heterogeneous cell population including mononuclear
phagocytes and polymorphonuclear granulocytes, play a crucial role in
the host defense at barrier tissues. Phagocytes internalize and process
invading pathogens, and thereby contribute directly to pathogen
clearance as well as to activation of the adaptive immune response via
antigen presentation [1,2]. However, the defense mechanisms of pha-
gocytes can also be harmful to the host. For example, excessive pro-
duction of Reactive Oxygen Species (ROS) by phagocytes causes tissue
injury and has been implicated in the pathogenesis of several in-
flammatory diseases, such as pulmonary fibrosis, atherosclerosis and
atopic dermatitis (AD) [3,4]. Therefore, the activity of phagocytes
needs to be tightly regulated.
Phagocytes are regulated, among others, by inhibitory receptors,
also known as immune checkpoints. These receptors inhibit several
phagocyte effector functions, including ROS production, cytokine pro-
duction and phagocytosis [5]. Most inhibitory receptors relay in-
hibitory signals via immunoreceptor tyrosine-based inhibitory motifs
(ITIMs) in the intracellular tail [6]. The expression pattern of immune
inhibitory receptors varies: receptors can be widely expressed or re-
stricted to specific cell types, tissues or activation states. For example,
the inhibitory collagen receptor LAIR-1 is constitutively expressed on
most lymphocytes [7], but on neutrophils it is only expressed upon
activation and in inflamed tissue [8]. The expression pattern of a re-
ceptor is pivotal for its biology, as it dictates where and when the re-
ceptor can exert its function.
We have previously identified Signal Inhibitory Receptor on
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Leukocytes-1 (SIRL-1) as an ITIM-bearing inhibitory receptor that is
expressed on circulating human monocytes and granulocytes, but ab-
sent on lymphoid cells [9–11]. Crosslinking of SIRL-1 with an agonistic
antibody inhibits Fc Receptor (FcR) induced ROS production [12,9,13]
and neutrophil extracellular trap (NET) formation [12,14]. The gene
encoding SIRL-1, VSTM1, contains a single nucleotide polymorphism
(SNP) rs612529T/C in its promoter region that dictates expression
(Frequency of C-allele: in Caucasians 15.8%, in Chinese 36.7%, in Ja-
panese 25.6% [9]). In individuals with rs612529C/C genotype, SIRL-1
expression on monocytes is almost completely absent, whereas SIRL-1
expression on granulocytes does not associate with rs612529 [9].
rs612529C also associates with an increased risk at AD [9].
Even though SIRL-1 expression has been well characterized on
peripheral blood granulocytes and monocytes, SIRL-1 expression in
barrier tissues and the influence of rs612529 hereon is currently un-
known. In this study, we used flow cytometry, cell sorting and qRT-PCR
to examine SIRL-1 expression on human phagocytes in peripheral blood
and in the barrier tissues skin, colon, and lung. We show that SIRL-1 is
expressed on granulocytes in these tissues, but that SIRL-1 expression
on mononuclear phagocytes differs between tissues and cell types.
2. Materials and methods
2.1. Tissue source
Peripheral blood was obtained from healthy volunteers. Healthy
skin from Caucasian donors was obtained from discarded material after
cosmetic abdominal or breast reduction surgery. AD patient skin was
obtained from 4mm punch biopsies from lesional skin, non-lesional
skin, and non-lesional skin 24 h after the initiation of an atopy patch
test (APT). APT was performed by application of house dust mite ex-
tract to the patients’ back, as previously described [15]. Colon biopsies
were obtained from Ulcerative Colitis or Crohn’s disease patients who
were in remission for at least four years. Lung tissue was obtained from
lung cancer patients during surgical tumor removal; for this study a
piece of non-malignant tissue was used. All samples were collected in
accordance with the Institutional Review Board of the University
Medical Center (UMC) Utrecht and Amsterdam UMC.
2.2. PBMC isolation
PBMCs were isolated by density gradient centrifugation of sodium-
heparinized peripheral blood over Ficoll-Paque (Amersham
Biosciences). PBMCs were washed and suspended in PBS containing 2%
(v/v) heat-inactivated fetal calf serum (FCS; Sigma-Aldrich) before
further use.
2.3. Digestion of skin tissue
For flow cytometric analysis, healthy whole skin was digested with
a Whole Skin Dissociation Kit (Miltenyi) according to manufacturer’s
instructions, using overnight incubation without Enzyme P.
For qRT-PCR analysis of sorted healthy skin cell populations, dermis
and epidermis were digested separately. Skin was shaved with a der-
matome to get the upper 0.3mm, washed with PBS, and incubated
5min with 100mg/mL gentamycin (Duchefa) to kill bacteria. Skin was
incubated overnight at 4 °C with 0.2% (w/v) dispase II (Roche) to se-
parate dermis and epidermis. Dermis was digested for 1.5 h in IMDM
(Lonza) supplemented with 0.5% (w/v) collagenase D (Sigma-Aldrich),
30 U/mL DNAse-I (Roche) and 1% (v/v) FCS. Epidermis was digested
for 0.5 h in PBS supplemented with 0.25% (w/v) Trypsin (Invitrogen)
and 0.2% EDTA (Invitrogen). Both digestions were performed at 37 °C
under gentle agitation, and quenched by adding FCS. Single cell sus-
pensions were obtained by thorough vortexing and filtering of the cells
over a single cell filter chamber and a 70 μm cell strainer. Next, epi-
dermal cells were treated with 12 U/mL DNAse-I and again filtered over
a 70 μm cell strainer, followed by Ficoll gradient centrifugation and
harvesting of cells from the interphase. Finally, epidermal and dermal
cells were washed and suspended in FACS buffer (PBS supplemented
with 2% (v/v) FSC, 1% (w/v) bovine serum albumin (BSA; Sigma-
Aldrich), 1% (v/v) human serum (HS; Sigma-Aldrich) and 0.1% (v/v)
sodium azide) before further use.
2.4. Digestion of colon tissue
Biopsies from the colon were collected in ice-cold Hank’s Balanced
Salt Solution (HBSS; Gibco) supplemented with 2% (v/v) FCS, 1% (v/v)
penicillin–streptomycin (PS; Gibco) and 1% (v/v) Amphotericin B
(Gibco). Next, 1 mM DTT (Sigma-Aldrich) was added to the solution
and the biopsy was incubated 10min at 4 °C under gentle agitation.
After thorough vortexing and one wash with supplemented HBSS, the
biopsy was digested with 1mg/mL collagenase IV (Sigma-Aldrich) in
supplemented RPMI 1640 (10% FCS, 1% PS, 1% Amphotericin B), for
1 h at 37 °C under gentle agitation. The biopsy was suspended by
pressing it through a 18.5-19G needle and a 70 µm cell strainer. Cells
were then washed and suspended in supplemented RPMI 1640 before
further use.
2.5. Digestion of lung tissue
Lung biopsies were rinsed with PBS, cut thoroughly, and digested in
IMDM supplemented with 125 ug/mL liberase (Roche), 100 ug/mL
DNAse-I and 5% (v/v) HS, for 45min at 37 °C or overnight at 4 °C. The
digestion was quenched with FCS, and a single cell suspension was
obtained by vortexing and filtering of the cells over a 70 μm cell
strainer. Erythrocytes were lysed by incubation with erythrocyte lysis
buffer (containing 0.155mM NH4Cl (Sigma-Aldrich), 1 mM KHCO3
(Merck KGaA), and 80 μM EDTA) for 10min on ice. After one wash with
PBS and one wash with MACS buffer (PBS supplemented with 0.5%
BSA, 2% FCS, 1% HS and 2mM EDTA), cells were frozen in HBSS with
50% (v/v) FCS and 10% (v/v) DMSO (Sigma-Aldrich) and stored in
liquid N2. Before flow cytometry, cells were thawed by drop wise ad-
dition of HBSS with 10% (v/v) FCS and washing with MACS buffer.
2.6. Flow cytometry and cell sorting
Cells were incubated with 5% (v/v) mouse serum (Equitech-Bio) in
PBS to block aspecific binding by Fc receptors. For cells from digested
tissue, this incubation was combined with viability dye APC-eFluor 780
(eBioscience). Subsequently, cells were stained with fluorochrome-
conjugated antibodies diluted in Brilliant Stain buffer (BD Biosciences),
see Supplementary Table 1 for an overview of the antibodies used. Flow
cytometry was performed on an LSRFortessa (BD Biosciences); cell
sorting was performed on a FACSAria III (BD Biosciences). Data were
analyzed using FlowJo software (Treestar, Ashland, OR). Cell subsets
were gated based on their typical surface marker expression [16,1,17],
see Supplementary Figs. 1–4 for the gating strategy used).
2.7. qRT-PCR
Sorted cells from the skin were collected in FACS buffer, centrifuged
and taken up in 350 µl RTL buffer (Qiagen) supplemented with 0.14M
2-mercaptoethanol (Sigma-Aldrich). RNA was isolated with the RNeasy
mini KiT (Qiagen) and cDNA was synthesized with the iScript reverse
transcription kit (Bio-Rad). Subsequently, qRT-PCR was performed with
SYBR Select Master Mix (Life Technologies) on 10 ng cDNA input per
reaction on a QuantStudio 12 K Flex (Applied Biosystems). Primers
were used that specifically amplify VSTM1-v1, the primary splice form
that encodes membrane-bound SIRL-1.
SIRL-1 mRNA expression was represented relative to GAPDH ex-
pression, using the formula ‘relative expression=2^(Ct(average of re-
ference genes)-Ct(target)).
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Target Forward primer Reverse primer
VSTM1-v1 (SIRL-1) gacaacagcctcccatgagt tgaagatggcgacaaagatg
GAPDH agaaggctggggctcattt gaggcattgctgatgatcttg
2.8. Genotyping
DNA was isolated with the DNA Extract All Reagents Kit (Thermo
Fisher Scientific). The genotype of rs612529 was determined using a
TaqMan SNP Genotyping Assay and TaqMan GTXpress Master mix
(Thermo Fisher Scientific). All procedures were performed according to
manufacturer’s instructions.
2.9. Immunohistochemistry
Whole skin cryosections (7 μm) were fixed by immersion in 10% (v/
v) Neutral Buffered Formalin (Sigma-Aldrich). Next, slides were in-
cubated for 10min in 0.03% (v/v) hydrogen peroxide (Sigma-Aldrich)
and blocked for 20min with 2.5% (v/v) horse serum (ImmPress kit,
Vector Laboratories). Slides were stained by a 1 h incubation with anti-
SIRL-1 (clone 1A5, produced in house [10], anti-elastase (clone NP57,
DAKO) or an isotype control (SouthernBiotech), followed by a 30min
incubation with horse anti-mouse IgG-HRP (ImmPress kit, Vector La-
boratories) and a 10min incubation with AEC+Substrate-Chromogen
(DAKO). Slides were counterstained with Mayer’s Hematoxylin solution
(Sigma-Aldrich) and mounted with Entellan (VWR). Between each step,
slides were washed extensively with PBS 0.05% (v/v) Tween-20. All
procedures were performed at room temperature. Images were acquired
on a Zeiss Axiovision.
2.10. Data analysis
Statistical analysis was performed using GraphPad Prism software
(version 8.3.0). A mixed-effects model with Sidak’s correction for
multiple testing was used to compare SIRL-1 expression between per-
ipheral blood mononuclear phagocytes subsets of donors with
rs612529T/T genotype. The same test was used to compare SIRL-1
expression between donors with rs612529T/T and rs612529T/C gen-
otypes in each lung phagocyte subset. P values of < 0.05 were con-
sidered statistically significant. Statistics in the text indicate the per-
centage of SIRL-1+ cells as compared to the isotype control and are
reported as mean ± standard deviation.
3. Results
3.1. Monocyte subsets, but not pDCs and cDCs, express SIRL-1 in peripheral
blood
We have previously shown that SIRL-1 is highly and homogeneously
expressed on peripheral blood neutrophils and eosinophils
[12,8,9,13,10,18]. Here, we used flow cytometry to measure SIRL-1
expression on mononuclear phagocyte subsets in peripheral blood (For
gating strategy see Supplementary Fig. 1). SIRL-1 was expressed by all
monocyte subsets, with highest expression on classical (c) monocytes
(CD14+CD16-), intermediate expression on intermediate (i) monocytes
(CD14+CD16+), and lowest expression on nonclassical (nc) monocytes
(CD14dimCD16+) and slanMonocytes, a subset of ncMonocytes (Fig. 1A,
B). SIRL-1 was absent on plasmacytoid dendritic cells (pDC), CD141+
DCs (‘cDC1’) and CD1c+ DCs (‘cDC2’) (Fig. 1A, C). However, a subset of
CD141-CD1c- DCs expressed SIRL-1 in all donors (Fig. 1A, D). As CD141-
CD1c- DCs are not well described, we backgated these SIRL-1+ DCs
(data not shown) and confirmed their correct gating as CD3-CD19-C56-
HLA-DR+CD14-CD16-CD11c+CD141-CD1c- cells (Supplementary
Fig. 1).
In line with our previous findings [9], we found that SIRL-1 ex-
pression was lower on monocytes from a donor with rs612529T/C
genotype and absent on monocytes from a donor with rs612529C/C
genotype (Fig. 1B). The percentage of SIRL-1+ CD141-CD1c- DCs was
not clearly affected by rs612529 (Fig. 1D). Taken together, these data
show that SIRL-1 is expressed by all monocyte subsets in peripheral
blood, but not by cDCs and pDCs.
3.2. SIRL-1 is expressed by very few mononuclear phagocytes in the skin
We previously reported that rs612529C associates with an increased
risk at AD [9], which led to the hypothesis that low SIRL-1 expression
on monocytes or monocyte-derived cells in the skin predisposes for AD.
Therefore, we used flow cytometry to examine SIRL-1 expression in
healthy human skin (For gating strategy see Supplementary Fig. 2).
SIRL-1 was not detected on autofluorescent dermal macrophages (MΦ),
CD1c+ DCs or CD141+ DCs in the skin (Fig. 2A). Low SIRL-1 expression
was found on a very small percentage of CD14+ monocyte-derived
macrophages (Mo-MΦ) in all four donors with rs612529T/T genotype
(2.13 ± 0.54% SIRL-1+ cells). Of note, in CD14+ Mo-MΦ from an
individual with rs612529T/C genotype, an even lower percentage of
cells expressed SIRL-1 (0.42% SIRL-1+ cells).
Tissue digestion may have altered surface receptor expression, so to
validate these results we used qRT-PCR to determine SIRL-1 mRNA
levels in sorted mononuclear phagocytes from the skin. Compared to
PBMC, SIRL-1 mRNA levels were approximately 100-fold lower in
CD14+ Mo-MΦ from donors with rs612529T/T genotype, and levels
were 500–1000-fold lower or undetectable in CD14+ Mo-MΦ from
donors with rs612529T/C genotype and in MΦ, dermal DCs and
Langerhans cells (LCs) (Fig. 2B). Together, this confirmed that SIRL-1
expression on mononuclear phagocytes in healthy skin is very low or
absent, and is lower in CD14+ Mo-MΦ from donors with rs612529T/C
genotype.
Lastly, we used immunohistochemistry (IHC) to examine SIRL-1
expression in AD skin. No SIRL-1 staining was detectable in healthy
skin, AD non-lesional skin, and AD lesional skin, compared to isotype
control (Fig. 2C). In contrast, several SIRL-1+ cells and elastase+
granulocytes were found in skin from an AD patient who received an
atopy patch test [15] (Fig. 2C), suggesting that SIRL-1 may be expressed
by skin infiltrating granulocytes.
In summary, we show that SIRL-1 is expressed on a very low number
of cells in healthy skin and AD skin.
3.3. Eosinophils in the colon express SIRL-1
To investigate SIRL-1 expression in another human barrier tissue,
we analyzed cells from a colon biopsy by flow cytometry (For gating
strategy see Supplementary Fig. 3). Because of varying degrees of
background signal in tissue cells, the MFI of anti-SIRL-1 stained cells
was normalized by subtracting the MFI of isotype stained cells. As in
skin, SIRL-1 was completely absent on CD11c+ DCs and lowly ex-
pressed on a small percentage of mature CD206+ MΦ and immature
CD206- Mo-MΦ (Fig. 3A). More SIRL-1+ cells were found in immature
CD206- Mo-MΦ from two donors with rs612529T/T genotype (8.29%
and 11.90% SIRL-1+ cells) compared to two donors with rs612529T/C
genotype (1.28% and 0% SIRL-1+ cells)
Eosinophils reside in the colon under homeostatic conditions [19].
In contrast to mononuclear phagocytes in the colon, SIRL-1 was highly
expressed on these colonic eosinophils. This expression was unaffected
by rs612529C (Fig. 3B), which corresponds with our earlier findings
that SIRL-1 expression on blood granulocytes does not associate with
rs612529C [9]. Together, these results show that in the colon, SIRL-1 is
mostly absent on mononuclear phagocytes, but highly expressed on
eosinophils.
3.4. Lung monocytes express SIRL-1
Lastly, we determined SIRL-1 expression on immune cells in human
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lung by flow cytometry (for gating strategy see Supplementary Fig. 4).
In contrast to mononuclear phagocytes in skin and colon, SIRL-1 was
highly expressed on lung cMonocytes (CD206-CD14+CD16-) (Fig. 4A,
B). Similar to blood, SIRL-1 expression was intermediate on iMonocytes
and lowest on ncMonocytes (Fig. 4B). SIRL-1 expression was sig-
nificantly lower on lung cMonocytes and ncMonocytes from donors
with rs612529T/C genotype compared to donors with rs612529T/T
genotype (Fig. 4B). SIRL-1 was also expressed by a subset of interstitial
macrophages (12.54 ± 10.77% SIRL-1+ cells), but absent on alveolar
macrophages, pDCs and CD11c+ DCs (Fig. 4A, B).
SIRL-1 was undetectable on mast cells in the lung, but highly ex-
pressed by neutrophils and, although at more variable levels, by eosi-
nophils (Fig. 4A, C). In line with findings from blood [9] and colon,
there was no effect of rs612529C on SIRL-1 expression by neutrophils
and eosinophils (Fig. 4C). In summary, these results show that SIRL-1 is
expressed by subsets of mononuclear phagocytes and granulocytes in
the lung.
3.5. SIRL-1 is differentially expressed between non-diseased tissues from the
GTEx consortium
The lung tissue in which we examined SIRL-1 expression was de-
rived from lung cancer patients, and malignant tissue might affect SIRL-
1 expression in healthy adjacent tissue. Therefore we used the
Genotype-Tissue Expression (GTEx) RNA sequencing database of gene
expression in non-diseased tissues to analyze VSTM1 expression
[20,21]. VSTM1 mRNA expression was highest in blood, pituitary
gland, spleen, lung and testis, whereas it was mostly absent in colon and
skin (Supplementary Fig. 5). This corresponds to the SIRL-1 protein
expression we found on mononuclear phagocytes in blood, skin, colon
and lung, suggesting that the SIRL-1 expression we report is re-
presentative for SIRL-1 expression in healthy tissues.
4. Discussion
Phagocytes are pivotal players in host defense, but excessive use of
their effector mechanisms can cause immunopathology. Therefore,
phagocyte activity is controlled by several mechanisms, including the
Fig. 1. SIRL-1 is expressed on monocyte
subsets, but not on pDCs and cDCs in
peripheral blood. PBMCs were isolated
from peripheral blood of healthy human
donors and analyzed by flow cytometry (See
Supplementary Fig. 1 for the gating
strategy). (A) Panels show representative
histograms of the fluorescence intensity of
mononuclear phagocyte subsets stained
with a SIRL-1 antibody (open histogram) or
an isotype control (closed histogram). The
dot plot insert of CD141-CD1c- DCs shows
the fluorescence intensity of anti-SIRL-1
stained cells on the x-axis, and SSC-A on the
y-axis. The gate shows the percentage of
SIRL-1+ cells compared to the isotype con-
trol. The donor’s genotype is rs612529T/T
(n=8–13). (B-C) Median fluorescence in-
tensity (MFI) of monocyte subsets (B) and
DC subsets (C) stained with a SIRL-1 anti-
body. (D) Percentage of SIRL-1+ cells in DC
subsets. (B-D) Each symbol represents one
donor, the bar indicates the mean. Geno-
types of rs612529 are indicated with filled
circles (T/T, n=13), open circles (T/C,
n= 1) or filled triangles (C/C, n=1).
SlanMo’s were analyzed in less donors: T/T,
n= 8; T/C, n= 1; C/C, n=0. A mixed-ef-
fects model with Sidak’s correction for
multiple testing was used to compare SIRL-1
expression between cell subsets of donors
with T/T genotype, ****p < 0.0001,
***p < 0.001, **p < 0.01. cMo, classical
monocytes; iMo, intermediate monocytes;
ncMo, nonclassical monocytes; slanMo, slan
monocytes; pDC, plasmacytoid DC.
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expression of inhibitory receptors [5]. SIRL-1 is a functional inhibitory
receptor that is expressed on circulating monocytes and granulocytes
[9,10]. Here, SIRL-1 expression was examined in peripheral blood and
barrier tissues, including skin, colon and lung. SIRL-1 was expressed by
virtually all neutrophils and eosinophils in these barrier tissues. In
contrast, SIRL-1 was expressed by few mononuclear phagocytes in skin
and colon, yet highly expressed by lung classical monocytes.
SIRL-1 was not expressed on pDCs and cDC subsets in peripheral
blood and barrier tissues (Fig. 1A, Fig. 2A, Fig. 3A, Fig. 4A). This is in
apparent conflict with a previous report, in which we showed SIRL-1
expression by 30% of peripheral blood DCs [10]. These outcomes can
be explained by different gating strategies that were used to identify
DCs. At the time, DCs were defined as HLA-DR+CD14-, without ex-
cluding CD16+ cells. However, in recent protein and RNA single-cell
analyses, CD16+ DCs were found to be more similar to ncMonocytes
[22,23]. Therefore, cells that were previously gated as SIRL-1 positive
CD16+ DCs were in this study defined as ncMonocytes. Remarkably, a
small subset of CD141-CD1c- DCs did express SIRL-1 in all donors ex-
amined (Fig. 1D). These ‘double negative’ DCs are poorly described in
literature, but a single cell RNA sequencing study described a CD141-
CD1c- DC subset in peripheral blood, which were named DC4s [24].
However, DC4s expressed CD16 and were therefore in later studies also
described as ncMonocytes [22,23]. In contrast, the CD141-CD1c- DCs
we describe here are CD16 negative. Further research is warranted to
clarify whether SIRL-1 expressing CD141-CD1c- DCs are a distinct
subset.
We previously reported that rs612529C associates with low SIRL-1
expression on monocytes [9]. Here, we extended this into tissue. SIRL-1
expression was significantly lower in lung cMonocytes and ncMono-
cytes from individuals carrying a rs612529C allele (Fig. 4B). A similar
trend was observed in CD14+ Mo-MΦ in the skin and immature CD206-
Mo-MΦ in the colon, even though SIRL-1 levels were overall very low in
these cells. On eosinophils and neutrophils in colon and lung, SIRL-1
expression was not affected by the genotype of rs612529 (Fig. 3B,
Fig. 4C), which is in correspondence with findings from peripheral
blood granulocytes [9].
Notably, rs612529C also associates with an increased risk at AD [9].
This association suggests a relationship between rs612529C, abrogated
SIRL-1 expression on monocytic cells, and AD pathogenesis. We hy-
pothesized that SIRL-1 is expressed by skin-resident mononuclear
Fig. 2. SIRL-1 expression on mono-
nuclear phagocytes in skin is very low or
absent. (A) Healthy human skin biopsies
were digested and analyzed by flow cyto-
metry (See Supplementary Fig. 2 for the
gating strategy). Panels show representative
histograms of the fluorescence intensity of
mononuclear phagocyte subsets stained
with a SIRL-1 antibody (open histogram) or
an isotype control (closed histogram). The
dot plot insert of CD14+ Mo-MΦ shows the
fluorescence intensity of anti-SIRL-1 stained
cells on the x-axis, and SSC-A on the y-axis.
The gate shows the percentage of SIRL-1+
cells compared to the isotype control. The
donor’s genotype is rs612529T/T (n=4).
(B) Human skin biopsies were separated into
dermis and epidermis, followed by digestion
and FACS sorting. mRNA was isolated from
the sorted cell subsets and SIRL-1 mRNA
expression was analyzed by qRT-PCR. Ex-
pression was normalized to GAPDH expres-
sion, and expression below the detection
limit was set at a value below 10-4. Each
symbol represents one donor. Genotypes of
rs612529 are indicated with filled circles
(T/T) or open circles (T/C). PBMC, n= 2;
CD14+ Mo-MΦ, n= 7; MΦ, n= 6, dermal
DCs, n= 7; LCs, n= 3. The vertical line
indicates that PBMCs were collected from
different donors and used for reference. (C)
Human skin cryosections were stained for
presence of SIRL-1 or elastase. The sections
derived from donors with rs612529T/T
genotype and include healthy donor skin
(upper panels), atopic dermatitis (AD) non-
lesional skin (middle left panel), AD lesional
skin (middle right panel) or skin from an AD
patient that underwent an atopy patch test
(APT, lower panels). Shown are re-
presentative images of≥ 3 donors. Magni-
fication: upper and lower panel 200x,
middle panel 400x. PBMC, peripheral blood
mononuclear cell; MΦ, macrophage, Mo-
MΦ, monocyte-derived macrophage; LC,
Langerhans cell.
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phagocytes, and that abrogation of this expression in individuals with
rs612529C genotype leads to lack of inhibitory signaling via SIRL-1.
This, in turn, could lead to hyperactivation of skin-resident mono-
nuclear phagocytes and thereby contribute to skin inflammation in AD.
However, mononuclear phagocytes in the skin expressed no or very low
levels of SIRL-1, in donors from all rs612529 genotypes, which argues
against a major role of SIRL-1 in the regulation of these cells in the skin
(Fig. 2A). Therefore it remains to be elucidated if and how the absence
of SIRL-1 expression on monocytes in individuals with rs612529C
genotype contributes to the development of AD. Possibly, monocytes
that are recruited to inflamed skin express SIRL-1, and abrogation of
SIRL-1 expression in this time frame could predispose for AD. Alter-
natively, mononuclear phagocytes with abrogated SIRL-1 expression
could play a role in AD pathogenesis in a different location than in the
skin, for example in the lymph nodes. Of note, CD14+ Mo-MΦ in the
skin expressed SIRL-1 mRNA, albeit at very low levels compared to
PBMCs, indicating that these cells have the potential to express SIRL-1
protein (Fig. 2B). In the flow cytometry analysis, this protein expression
may have been partially lost by the tissue digestion.
This study is limited by the availability of healthy human tissue.
Firstly, the sample size of tissue biopsies is relatively small. Secondly,
colon and lung tissue were derived from patients with (former) disease:
colon biopsies were taken from Ulcerative Colitis or Crohn’s disease
patients that were in remission for at least four years, and lung biopsies
were obtained from non-malignant tissue of lung cancer patients.
Because these disease states might alter SIRL-1 expression, we com-
pared our data to SIRL-1 mRNA expression found in the GTEx dataset,
which contains RNA sequencing data of human non-diseased tissues
[20]. In the GTEx dataset, SIRL-1 expression was relatively high in
blood and lung, and absent in colon and skin (Supplementary Fig. 5),
resembling the SIRL-1 protein expression we found on mononuclear
phagocytes in these tissues. This supports that the SIRL-1 expression we
measured in this study is representative for SIRL-1 expression in healthy
tissues. SIRL-1 expression was absent in the GTEx analysis of the colon,
whereas we detected SIRL-1 expression on colon eosinophils. Granu-
locytes contain low total transcript levels [25], and therefore the SIRL-1
transcripts of eosinophils may have been underrepresented in the RNA
sequencing analysis.
Mononuclear phagocyte subsets have distinct ontogenies. For
example, macrophages can originate either from circulating monocytes
that extravasate into the tissue, or from yolk-sac or fetal liver-derived
cells that already populate the tissue during embryonic development
[1]. We show that most macrophages in tissues do not express SIRL-1.
However, a small percentage of macrophages expressed low levels of
SIRL-1, including CD14+ Mo-MΦ in the skin, immature CD206- Mo-MΦ
and mature CD206+ MΦ in the colon, and interstitial MΦ in the lung.
These macrophage subsets are all considered to be of monocytic origin
[16,26,1,27,28]. In contrast, autofluorescent dermal MΦ and alveolar
MΦ, both considered to be of fetal origin [26,1], did not express SIRL-1.
Even though we cannot confirm the development of SIRL-1 expression
over time, these results suggest that monocytes downregulate SIRL-1
expression when they enter the tissue and differentiate into macro-
phages.
We can only speculate as to why monocytes in lung express SIRL-1,
whereas mononuclear phagocytes in colon and skin do not.
Mechanistically, SIRL-1 expression may be directly maintained by a
factor specifically present in the lung. Alternatively, SIRL-1 may be
predominantly expressed by undifferentiated monocytes, and a factor in
the lung keeps monocytes in this state. Indeed, even though it has long
been thought that all monocytes which enter the tissue differentiate
into MΦ or DCs, healthy human lungs contain undifferentiated mono-
cytes in steady state [29]. Of note, lung interstitial macrophages, which
are at least partially monocyte-derived (reviewed by [28], express very
low levels of SIRL-1 (Fig. 4A, B). This argues that it is not the lung
environment per se which maintains SIRL-1 expression on mononuclear
phagocytes, but rather the differentiation status of the monocytes.
Functionally, SIRL-1 may inhibit ROS production in lung monocytes
and granulocytes, as it has been described for these cells from healthy
donor peripheral blood [9,13] and sputum from infants with severe
Respiratory Syncytial Virus bronchiolitis [12]. In addition, SIRL-1 may
have yet unexplored effects on the regulatory function of monocytes,
for example cytokine production. Based on intravital imaging in mice,
lung monocytes were suggested to be mainly involved in scavenging of
particles to clean up airways and blood [30]. Lungs are continuously
exposed to inhaled particles, many of which are non-pathogenic. In-
hibiting the immune response to such particles, for example by in-
hibitory receptor signaling, is therefore likely to be beneficial to the
host.
Fig. 3. SIRL-1 is expressed by eosinophils
in the colon. Human colon biopsies were
digested and analyzed by flow cytometry
(See Supplementary Fig. 3 for the gating
strategy). (A) Panels show representative
histograms of the fluorescence intensity of
immune cells stained with a SIRL-1 antibody
(open histogram) or an isotype control
(closed histogram). The dot plot inserts of
CD206- Mo-MΦ and CD206+ MΦ show the
fluorescence intensity of anti-SIRL-1 stained
cells on the x-axis, and SSC-A on the y-axis.
The gate shows the percentage of SIRL-1+
cells compared to the isotype control. The
donor’s genotype is rs612529T/T (n=2).
(B) Median fluorescence intensity (MFI) of
immune cells stained with a SIRL-1 anti-
body, minus the MFI of cells stained with an
isotype control. Each symbol represents one
donor. Genotypes of rs612529 are indicated
with filled circles (T/T, n= 2) or open cir-
cles (T/C, n=2). Mo-MΦ, monocyte-de-
rived macrophage.
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In conclusion, we show that SIRL-1 is differentially expressed on
human phagocyte subsets in barrier tissues. SIRL-1 is ubiquitously ex-
pressed on granulocytes, whereas expression on monocytes is genotype-
and tissue-specific. Identification of the ligand of SIRL-1 will add to the
understanding of the context in which SIRL-1 exerts its biological
functions.
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Fig. 4. SIRL-1 is expressed by lung monocytes. Human lung biopsies were digested and analyzed by flow cytometry (See Supplementary Fig. 4 for the gating
strategy). (A) Panels show representative histograms of the fluorescence intensity of mononuclear phagocytes and granulocytes stained with a SIRL-1 antibody (open
histogram) or an isotype control (closed histogram). The donor’s genotype is rs612529T/T (n=3). (B-C) Median fluorescence intensity (MFI) of mononuclear
phagocytes (B) and granulocytes (C) stained with a SIRL-1 antibody, minus the MFI of the same cell type stained with an isotype control. Each symbol represents one
donor. Genotypes of rs612529 are indicated with filled circles (T/T, n=3) or open circles (T/C, n= 3). A mixed-effects model with Sidak’s correction for multiple
testing was used to compare SIRL-1 expression between donors with rs612529T/T and rs612529T/C genotype in each cell subset, *p < 0.05. cMo, classical
monocytes; iMo, intermediate monocytes; ncMo, nonclassical monocytes; MΦ, macrophage.
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